Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 332

The DOI matches its Crossref record; 197 of the 197 references it cites were found in a registry or an index.

Liquid biopsy in breast cancer: A comprehensive review

Alimirzaie, Sahar, Bagherzadeh, Maryam, Akbari, Mohammad R.·2019·Clinical Genetics

Abstract

Breast cancer is the most common cancer among women worldwide. Due to its complexity in nature, effective breast cancer treatment can encounter many challenges. Traditional methods of cancer detection such as tissue biopsy are not comprehensive enough to capture the entire genomic landscape of breast tumors. However, with the introduction of novel techniques, the application of liquid biopsy has been enhanced, enabling the improvement of various aspects of breast cancer management including early diagnosis and screening, prediction of prognosis, early detection of relapse, serial sampling and efficient longitudinal monitoring of disease progress and response to treatment. Various components of tumor cells released into the blood circulation can be analyzed in liquid biopsy sampling, some of which include circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell‐free RNA, tumor‐educated platelets and exosomes. These components can be utilized for different purposes. As an example, ctDNA can be sequenced for genetic profiling of the tumors to enhance individualized treatment and longitudinal screening. CTC plasma count analysis or ctDNA detection after curative tumor resection surgery could facilitate early detection of minimal residual disease, aiding in the initiation of adjuvant therapy to prevent recurrence. Furthermore, CTC plasma count can be assessed to determine the stage and prognosis of breast cancer. In this review, we discuss the advantages and limitations of the various components of liquid biopsy used in breast cancer diagnosis and will expand on aspects that require further focus in future research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cge.13514

Cites

197 of 197 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 197 references

Research works printed but not linked: 15

  1. 10.1200/jco.2015.33.15_suppl.e19082 · doi:10.1200/jco.2015.33.15_suppl.e19082
  2. 10.1373/clinchem.2014.229476 · doi:10.1373/clinchem.2014.229476
  3. 10.1196/annals.1448.023 · doi:10.1196/annals.1448.023
  4. 10.1186/cc4932 · doi:10.1186/cc4932
  5. Ballester L, 2017, Evaluating circulating tumor DNA from cerebrospinal fluid, Cancer Genet, 34, 214
  6. 10.1200/jco.2015.33.3_suppl.518 · doi:10.1200/jco.2015.33.3_suppl.518
  7. 10.1136/esmoopen-2017-000253 · doi:10.1136/esmoopen-2017-000253
  8. Hannafon BN, 2017, The role of metastasis‐associated protein 1 (MTA1) in breast cancer exosome‐mediated intercellular communication, FASEB J, 31, 178.6
  9. 10.1056/NEJMsr1613680 · doi:10.1056/nejmsr1613680
  10. 10.3389/fpubh.2014.00087 · doi:10.3389/fpubh.2014.00087
  11. 10.1007/978-3-319-55661-1_9 · doi:10.1007/978-3-319-55661-1_9
  12. 10.3233/CBM-2012-0263 · doi:10.3233/cbm-2012-0263
  13. Tomaszewski JJ, 2014, Heterogeneity and renal mass biopsy: a review of its role and reliability, Cancer Biol Med, 11, 162
  14. 10.1016/j.jpedsurg.2016.02.066 · doi:10.1016/j.jpedsurg.2016.02.066
  15. 10.1038/leu.2008.227 · doi:10.1038/leu.2008.227

Cited by

See all 332

Metadata

Authors
Alimirzaie, S., Bagherzadeh, M., & Akbari, M. R.
Venue
Clinical Genetics
Publisher
Wiley
Published
2019-02-27
Volume
95
Issue
6
Pages
643-660
ISSN
  • 0009-9163 (ISSN-L)
  • 1399-0004
OpenAlex
W2911953146
Cited by
332
References
197
FWCI
11.68
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liquid biopsy in breast cancer: A comprehensive review. https://app.cochat.ai/papers/10.1111/cge.13514
The paper
Alimirzaie, S., Bagherzadeh, M., & Akbari, M. R. (2019). Liquid biopsy in breast cancer: A comprehensive review. Clinical Genetics. https://doi.org/10.1111/cge.13514

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.